Mammary analogue secretory carcinoma of the head and neck — Clinicopathological, imaging features and prognosis analysis

• Published in: Journal of radiation research and applied sciences Vol. 17; no. 2; p. 100914
• Main Authors: Liu, Runjia, Sun, Chuanzheng, Zhao, Likang, Zhou, Shiyu, Xie, Tao, Zhang, Ji, Tang, Dengpeng, Li, Lei, Xi, Yan
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.06.2024
• Subjects: Diagnosis; Diagnosis and treatment; Mammary analogue secretory carcinoma (MASC); Prognosis; Prognosis; Diagnosis; Diagnosis and treatment; Mammary analogue secretory carcinoma (MASC)
• ISSN: 1687-8507; 1687-8507
• DOI: 10.1016/j.jrras.2024.100914

As a rare type of tumor reported in recent years, mammary analogue secretory carcinoma (MASC) is similar to secretory carcinoma in histological morphology, immunohistochemical expression and molecular genetic characteristics. Because of its low incidence, it is often impossible to accurately grasp its diagnosis and treatment in clinical practice. To analyze the characteristics of mammary analogue secretory carcinoma of the head and neck and explore the key points for diagnosis and individualized treatment of this disease. The clinical, imaging, immunohistochemical, pathological and genetic features of 5 cases with MASC of head and neck diagnosed in our hospital from 2021 to 2023 were analyzed retrospectively. Additionally, relevant literatures from home and abroad were reviewed and meta-analysis of the prognosis of this tumor was carried out. Ultrasonography, CT and MRI features in 5 patients lacked the typical acoustic features of malignant tumors. SSC microscopy of breast-like secretory carcinoma had a variety of morphologic structures. Immunohistochemistry was performed in 4 patients, and the immunophenotype was positive for S-100 (4/4), negative for DOG1 (3/3), and positive for Mammaglobin (2/2). The results of meta-analysis showed: During follow-up, the incidence of tumor recurrence or metastasis and mortality due to the disease were 10.3% in the group treated solely with surgery [95% CI (−1.463,1.669) P = 0.898], 52.4% in the other group [95% CI (−1.059,2.106). P = 0.517], and the difference between the two groups was statistically significant (χ2 = 23.59, P = 1.19 × 10−6). MASC is a rare low-grade malignant tumor. Its clinical manifestations, imaging, immunohistochemistry, pathology, and gene detection characteristics provide a basis for preoperative diagnosis. If there are no malignant pathological signs such as vascular invasion, nerve invasion and distant metastasis, the maximum diameter of the tumor is ≤ 7 cm, and simple surgery is preferred regardless of lymph node metastasis.